Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Two-Component Disaggregation of ROE

Cytokinetics Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = ROA × Financial Leverage
Sep 30, 2023 = ×
Jun 30, 2023 = ×
Mar 31, 2023 = ×
Dec 31, 2022 = ×
Sep 30, 2022 = ×
Jun 30, 2022 = ×
Mar 31, 2022 = ×
Dec 31, 2021 = ×
Sep 30, 2021 = ×
Jun 30, 2021 = ×
Mar 31, 2021 = ×
Dec 31, 2020 = ×
Sep 30, 2020 = ×
Jun 30, 2020 = ×
Mar 31, 2020 = ×
Dec 31, 2019 = ×
Sep 30, 2019 = ×
Jun 30, 2019 = ×
Mar 31, 2019 = ×
Dec 31, 2018 = ×
Sep 30, 2018 = ×
Jun 30, 2018 = ×
Mar 31, 2018 = ×

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).


Return on Assets (ROA)
The ROA figures show a persistently negative trend throughout the analyzed periods, indicating that the company has not generated positive returns on its assets over time. Starting in late 2018, the negative ROA values deepen, reaching a peak negative value around September 2023 at -71.12%. There are fluctuations within this downward trajectory; for example, ROA improved slightly between December 2020 and June 2021, stabilizing around -23% to -27%, but then deteriorated again from late 2021 onwards. The consistent negative ROA suggests ongoing challenges with asset efficiency and profitability.
Financial Leverage
The financial leverage ratio exhibits significant variability over the periods. Early values in 2018 and early 2019 indicate moderate to high leverage, with a notable spike to 58.9 in March 2019. Following this peak, data are missing for several quarters, complicating the analysis. Resumed figures in late 2020 through mid-2022 reveal fluctuating leverage ratios mostly within the 3.17 to 8.51 range, with a high of 34.22 in December 2021, reflecting periods of increased debt relative to equity. The leverages generally indicate a reliance on borrowing, though the missing data limits a full continuous assessment.
Return on Equity (ROE)
Return on Equity values are uniformly negative during the recorded periods, with extreme negative values especially observed in the year 2019. Figures such as -3124.97% in June 2019 point to severe losses or negative equity scenarios. Later values through 2020 and 2021 remain significantly negative but fluctuate within a narrower range compared to 2019, suggesting ongoing but variable financial distress affecting shareholder returns. ROE shows a pattern somewhat aligned with ROA, emphasizing the overall lack of profitability and substantial financial challenges.

Three-Component Disaggregation of ROE

Cytokinetics Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Sep 30, 2023 = × ×
Jun 30, 2023 = × ×
Mar 31, 2023 = × ×
Dec 31, 2022 = × ×
Sep 30, 2022 = × ×
Jun 30, 2022 = × ×
Mar 31, 2022 = × ×
Dec 31, 2021 = × ×
Sep 30, 2021 = × ×
Jun 30, 2021 = × ×
Mar 31, 2021 = × ×
Dec 31, 2020 = × ×
Sep 30, 2020 = × ×
Jun 30, 2020 = × ×
Mar 31, 2020 = × ×
Dec 31, 2019 = × ×
Sep 30, 2019 = × ×
Jun 30, 2019 = × ×
Mar 31, 2019 = × ×
Dec 31, 2018 = × ×
Sep 30, 2018 = × ×
Jun 30, 2018 = × ×
Mar 31, 2018 = × ×

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).


The data reveals pronounced volatility and generally deteriorating trends in several key financial ratios over the examined periods.

Net Profit Margin (%)
This ratio consistently reflects substantial negative values throughout, indicating persistent losses. From the first reporting in December 2018 at -337.41%, the margin worsened sharply through 2019 and 2020, reaching extreme negative figures such as -1061.13% in March 2021. Despite minor fluctuations and some improvement in mid-2022 (-142.85% to -190.34%), the margin then steeply declined again in 2023, culminating in an unprecedented low near -6740% in September 2023. This pattern suggests escalating operational or extraordinary losses and a severely negative profitability situation.
Asset Turnover (ratio)
The asset turnover ratio, which measures how efficiently the company uses its assets to generate sales, exhibits low values across the periods, starting from 0.15 in March 2019 and generally declining or remaining stagnant around or below 0.1 in many quarters. Noteworthy exceptions include a slight increase to 0.2 in September 2022. However, the overall trend indicates consistently weak asset utilization relative to sales.
Financial Leverage (ratio)
This measure shows significant swings, with an initial moderate increase from 2.81 in March 2018 to a striking peak of 58.9 in March 2019, implying a dramatic rise in debt or liabilities relative to equity during that period. Following this peak, the data is partially incomplete, but leverage values once again surged to high levels such as 34.22 by December 2021 before missing data impedes a full trend analysis. The fluctuations denote an unstable capital structure with episodes of high reliance on external financing.
Return on Equity (ROE) (%)
ROE reflects deep negative returns on shareholders' equity, consistent with the poor profit margins. Recorded starting December 2018 at -409.84%, ROE deteriorated sharply by mid-2019 with a severe dip to -3124.97%, showcasing extreme inefficiencies or losses relative to equity capital. Subsequent quarters show continued negative ROE values frequently exceeding -90%, with a steep decline to nearly -945% in December 2021, highlighting sustained and significant erosion of shareholder value.

In summary, the company's financial performance over the observed quarters exhibits chronic and severe negative profitability, poor asset efficiency, highly fluctuating leverage with occasional spikes, and sustained negative returns on equity. These indicators collectively point to deep financial distress and pressing challenges in achieving operational stability and profitability.


Five-Component Disaggregation of ROE

Cytokinetics Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Sep 30, 2023 = × × × ×
Jun 30, 2023 = × × × ×
Mar 31, 2023 = × × × ×
Dec 31, 2022 = × × × ×
Sep 30, 2022 = × × × ×
Jun 30, 2022 = × × × ×
Mar 31, 2022 = × × × ×
Dec 31, 2021 = × × × ×
Sep 30, 2021 = × × × ×
Jun 30, 2021 = × × × ×
Mar 31, 2021 = × × × ×
Dec 31, 2020 = × × × ×
Sep 30, 2020 = × × × ×
Jun 30, 2020 = × × × ×
Mar 31, 2020 = × × × ×
Dec 31, 2019 = × × × ×
Sep 30, 2019 = × × × ×
Jun 30, 2019 = × × × ×
Mar 31, 2019 = × × × ×
Dec 31, 2018 = × × × ×
Sep 30, 2018 = × × × ×
Jun 30, 2018 = × × × ×
Mar 31, 2018 = × × × ×

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).


The analyzed quarterly financial data reveals several significant trends and noteworthy fluctuations in key financial metrics over the observed periods.

EBIT Margin (%)
The EBIT margin demonstrates persistently negative values throughout the periods with substantial volatility. Starting around -325% in late 2018, the margin further deteriorates, reaching extremes of -985% by early 2021 and declining to as low as approximately -6379% by the third quarter of 2023. This persistent negative and worsening margin suggests continual operating losses and increasing expense pressures relative to revenues over time.
Asset Turnover (ratio)
Asset turnover shows moderate variability, fluctuating mostly between 0.01 and 0.2 ratios. Values generally remain low, indicating limited efficiency in generating revenue from total assets. Notably, turnover dips to 0.01 during several quarters in 2023, signaling a decline in asset utilization efficiency in the most recent periods.
Financial Leverage (ratio)
Financial leverage exhibits considerable variation over the timeline. Initial ratios in early 2018 range from 2.8 to 8.1, followed by a sharp spike to about 58.9 in early 2019, suggesting a large increase in debt or equity structure adjustments during that timeframe. Subsequent quarters show fluctuating leverage, including moderate ratios in the 3 to 8 range and another peak nearing 34 by the end of 2020. The pattern indicates episodic reliance on debt or increased leverage, with intervals of stabilization.
Return on Equity (ROE) (%)
ROE figures are consistently negative over the periods where data is available, with drastic dips such as -409% in late 2018 and a profound low of -3125% shortly thereafter. Although some recovery occurs in mid to late periods, numbers continue to reflect substantial losses attributable to shareholders, indicating ineffective capital use and ongoing financial challenges.

Overall, the data reflects a company struggling with negative profitability and operational efficiency. Asset utilization remains weak and financial leverage is volatile, indicating variable capital structure strategies that may be responses to operating losses. The extreme negative margins and ROE underscore persistent financial distress, and the recent intensification in losses suggests continuing challenges without clear improvement trends in the analyzed quarters.


Two-Component Disaggregation of ROA

Cytokinetics Inc., decomposition of ROA (quarterly data)

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Sep 30, 2023 = ×
Jun 30, 2023 = ×
Mar 31, 2023 = ×
Dec 31, 2022 = ×
Sep 30, 2022 = ×
Jun 30, 2022 = ×
Mar 31, 2022 = ×
Dec 31, 2021 = ×
Sep 30, 2021 = ×
Jun 30, 2021 = ×
Mar 31, 2021 = ×
Dec 31, 2020 = ×
Sep 30, 2020 = ×
Jun 30, 2020 = ×
Mar 31, 2020 = ×
Dec 31, 2019 = ×
Sep 30, 2019 = ×
Jun 30, 2019 = ×
Mar 31, 2019 = ×
Dec 31, 2018 = ×
Sep 30, 2018 = ×
Jun 30, 2018 = ×
Mar 31, 2018 = ×

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).


Net Profit Margin
The net profit margin data indicates a consistent negative trend throughout the observed periods. Starting from the first available quarter in December 2018, the margin is deeply negative at -337.41%, and this unfavorable trend continues with fluctuations but generally worsening values. The margin notably deteriorates sharply in the quarters of 2023, reaching values such as -5422.19% and -6739.96%. This suggests significantly increasing losses relative to revenue over time, with the most severe negative margins appearing in the most recent quarters. The magnitude of these losses suggests either growing expenses or declining revenues, or a combination of both, impacting profitability considerably.
Asset Turnover
Asset turnover ratios, indicating the efficiency with which the company utilizes its assets to generate sales, show low values throughout the available data. The ratio starts at 0.15 in March 2019, peaks modestly at 0.20 in September 2022, but mostly remains below 0.20, with several quarters particularly in late 2022 and 2023 showing declines to around 0.01. This low and volatile asset turnover ratio reflects either limited sales generation from asset base or possible asset growth not matched by proportional sales increases, suggesting potential inefficiencies or shifts in operational focus.
Return on Assets (ROA)
Return on assets shows a persistently negative return across all reported quarters, indicating the company has not been profitable relative to its asset base during this period. ROA starts near -50% from late 2018 to 2019, fluctuating mildly but generally remaining within the range of negative 20s to negative 60s percent. In recent quarters of 2023, the ROA worsens further, reaching approximately -69% to -71%. This pattern highlights ongoing challenges in generating positive returns on assets, consistent with the negative net profit margins and low asset turnover. The trend accentuates the difficulty in translating asset holdings into profitable operations.

Four-Component Disaggregation of ROA

Cytokinetics Inc., decomposition of ROA (quarterly data)

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Sep 30, 2023 = × × ×
Jun 30, 2023 = × × ×
Mar 31, 2023 = × × ×
Dec 31, 2022 = × × ×
Sep 30, 2022 = × × ×
Jun 30, 2022 = × × ×
Mar 31, 2022 = × × ×
Dec 31, 2021 = × × ×
Sep 30, 2021 = × × ×
Jun 30, 2021 = × × ×
Mar 31, 2021 = × × ×
Dec 31, 2020 = × × ×
Sep 30, 2020 = × × ×
Jun 30, 2020 = × × ×
Mar 31, 2020 = × × ×
Dec 31, 2019 = × × ×
Sep 30, 2019 = × × ×
Jun 30, 2019 = × × ×
Mar 31, 2019 = × × ×
Dec 31, 2018 = × × ×
Sep 30, 2018 = × × ×
Jun 30, 2018 = × × ×
Mar 31, 2018 = × × ×

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).


EBIT Margin
The EBIT margin exhibits a consistently negative trend throughout the observed periods, indicating sustained operating losses. Starting from March 31, 2019, margins are extremely negative, ranging from approximately -325% to beyond -6,000% by the latest quarter ending September 30, 2023. The severity of the losses fluctuates, with some quarters such as March 31, 2021 (-985.77%) and September 30, 2023 (-5,142.17%) showing substantially larger negative margins. There is no evidence of recovery or stabilization, demonstrating ongoing operational challenges.
Asset Turnover
Asset turnover ratios remain generally low across the periods, reflecting limited revenue generated per unit of assets. The ratio varies in a narrow range from roughly 0.01 up to around 0.20. Notably, the asset turnover slightly improved around late 2022 (September 30, 2022 at 0.20) but then declined again to near 0.01 in the most recent quarters of 2023. Such low ratios suggest inefficient utilization of assets in producing sales.
Return on Assets (ROA)
Return on assets is consistently negative, which aligns with the losses reflected in the EBIT margin. ROA percentages vary between approximately -24% and worsening levels close to -71% in the most recent quarter. This decline in ROA over time signals increasing inefficiency in asset use to generate net income. The downturn becomes particularly pronounced from late 2022 through 2023, indicating deteriorating profitability relative to asset base.
Overall Trends and Insights
The company demonstrates persistently negative profitability metrics across EBIT margin and ROA, with no indication of improvement over multiple years. Asset turnover remains low, revealing challenges in converting assets into revenues efficiently. The worsening negative margins and returns in recent quarters suggest increasing operational and financial difficulties. These patterns highlight significant structural or market-related challenges impacting the ability to generate positive earnings or returns on invested assets.

Disaggregation of Net Profit Margin

Cytokinetics Inc., decomposition of net profit margin ratio (quarterly data)

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Sep 30, 2023 = × ×
Jun 30, 2023 = × ×
Mar 31, 2023 = × ×
Dec 31, 2022 = × ×
Sep 30, 2022 = × ×
Jun 30, 2022 = × ×
Mar 31, 2022 = × ×
Dec 31, 2021 = × ×
Sep 30, 2021 = × ×
Jun 30, 2021 = × ×
Mar 31, 2021 = × ×
Dec 31, 2020 = × ×
Sep 30, 2020 = × ×
Jun 30, 2020 = × ×
Mar 31, 2020 = × ×
Dec 31, 2019 = × ×
Sep 30, 2019 = × ×
Jun 30, 2019 = × ×
Mar 31, 2019 = × ×
Dec 31, 2018 = × ×
Sep 30, 2018 = × ×
Jun 30, 2018 = × ×
Mar 31, 2018 = × ×

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).


The analyzed financial indicators reveal a pronounced negative trend in profitability over the observed periods. Both EBIT Margin and Net Profit Margin consistently reflect substantial losses, which deepen markedly in the most recent quarters.

EBIT Margin
The EBIT Margin shows a progressive decline from early 2019 onwards. Initial negative values around -325% to -362% deteriorate further, reaching extreme negative figures beyond -900% in early 2021. Subsequently, while there is some fluctuation, the margin remains deeply negative, culminating in an extraordinary drop to over -5,000% in the last two quarters reported. This indicates escalating operational losses without recovery signs.
Net Profit Margin
Similar to the EBIT Margin, the Net Profit Margin also displays a sustained and severe downward trend. Starting near -337% in early 2019, the metric worsens steadily, crossing -1,000% in the first quarter of 2021. It then remains substantially negative with some oscillations but ultimately plunges to values around -5,400% to -6,700% in the latest reporting periods, confirming intensified net losses.

The absence of values for Tax Burden and Interest Burden precludes analysis of their impact on profitability. Nonetheless, the continual deepening of negative profitability margins clearly suggests significant operational challenges, likely driven by increased costs, decreased revenues, or both. This severe erosion in margins underscores the need for strategic interventions to stabilize and reverse the negative earnings trajectory.